NCT07787247招募中不适用
Pilot Study: Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Subject Study Completion
研究概览
简要总结
Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating weakness, which can worsen suddenly without a clear predictor. The hypothesis is that continuous monitoring of key aspects of patient physiology and activity coupled to rigorous telemedicine-performed examination has the potential to detect MG worsening which requires change in treatment with the benefit of avoiding need for hospitalization or emergent therapy. This study is to evaluate the reliability of the technology and patient compliance to the monitoring program
研究设计
- 研究类型
- 观察性
- 观察模型
- 队列研究
- 时间视角
- 前瞻性
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- Subject
- Has the capacity to understand and sign an informed consent form
- ≥18 years old
- Diagnosed with acquired autoimmune MG based on clinical syndrome and seropositivity for MG associated autoantibodies (AChR binding, MuSK, or LRP4 antibodies), and/or a decremental response on repetitive nerve stimulation, positive single fiber electromyography (EMG) or positive edrophonium test
- Subject has been previously evaluated in a face-to-face clinical encounter at participating study site or referral site within the prior 3 years
- Primary language is English, or equivalent level of English language fluency
- Required disease severity range previously judged by the Investigator. MGFA class 1-4a within 3 years of diagnosis without other chronic medical conditions, which compromise participation.
- Having MG-ADL score above 2 upon entrance to study
- Patients considered by study PI not to require hospitalization at time of entrance
- The patient has internet capability and a smart phone compatible with the apps required by the study.
排除标准
- Disease Specific Exclusion Criteria
- Inability to comply with study protocol for monitoring
- Current MGFA Severity Class IVb or V, or patients in remission with MGFA Class 0
- Any significant medical/psychiatric condition that, in the opinion of the Investigator, may interfere with interpretation of subject evaluation(s) or protocol compliance
- Any disorder that could limit ability to assess myasthenia gravis specific deficits (not including planned or recent thymectomy)
- Pregnancy, based on the evaluator's judgment, if the subject is deemed not safe to undergo evaluation or comply with study visit requirements.
- Lack of effective internet connection or ability to use study telemedicine station and monitors
- Home environment prevents use of study equipment
- Likelihood of leaving DC, Maryland, or Virginia area in year after initiation of study
- Subject is already participating in a research study -
结局指标
主要结局
Subject Study Completion
时间窗: 12 months
Proportion of subjects complete the 12-month study
Datasets retrieved from study assessments
时间窗: 12 months
Proportion of assessments provide data sets that can be analyzed
次要结局
- Myasthenia Gravis-Activities of Daily Living and Myasthenia Gravis-Core Examination(12 months)
- Subject Satisfaction(12 months)
- MG-ADL and MG-CE(12 months)
- Fitbit correlation(12 months)
- Hospital Anxiety and Depression Scale(12 months)
研究者
研究点 (1)
Loading locations...
标识符
- NCT 编号
- NCT07787247
- 其他研究编号
- MS056805_0001, 51550-1-EENS9212, NCR267243, 100
日期
- 首次提交
- (上个月)
- 首次发布
- (上个月)
- 主要完成日期
- (2年后)
- 研究完成日期
- (2年后)
- 最近核实
- (29天前)
- 最近更新
- (昨天)
监管与共享
- FDA 监管药物
- 否
- FDA 监管器械
- 否
- 是否有结果
- 否
相似试验
招募中
不适用
同适应症Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG CrisisMyasthenia GravisNCT07411963Centre Hospitalier Universitaire de Nice30
招募中
2 期
同适应症Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia GravisMyasthenia Gravis, MuSKMyasthenia GravisNCT06414954NMD Pharma A/S84
招募中
2 期
同适应症KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisGeneralized Myasthenia GravisMyasthenia GravisNCT06193889Kyverna Therapeutics66
终止
2 期
同适应症Study of ALXN2050 in Adult Participants With Generalized Myasthenia GravisGeneralized Myasthenia GravisMyasthenia GravisNCT05218096Alexion Pharmaceuticals, Inc.70
已完成
2 期
同适应症Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia GravisMyasthenia GravisOcular Myasthenia GravisNCT05045248American University of Beirut Medical Center10